



Anbio Biotechnology

Improving Prognosis by Decentralizing Diagnostics

Anbio

Forward-Looking Statements

Anbio Biotechnology Inc., or the Company, has filed a registration statement on Form F-1 (File No. 333-284106) with the U.S. Securities and Exchange Commission, or the SEC, for the offering to which this free writing prospectus relates. Before you invest, you should read the prospectus in the registration statement and other documents the Company has filed with the SEC for more complete information about the Company and this offering. Investors should rely upon the prospectus and any relevant free-writing prospectus for complete details. You may obtain these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, the Company, any underwriter, or any dealer participating in the offering will arrange to send you the prospectus if you request it by contacting AC Sunshine Securities LLC. at 200 E. Robinson Street, Suite 295 Orlando, FL 32801, via email: ycui@acsunshine.com. You may also access the Company's most recent prospectus dated 1/10/2025, which is included in Amendment No. 1 to the Company's registration statement on Form F-1 filed with the SEC on 1/10/2025, by visiting EDGAR on the SEC website at: <https://www.sec.gov/Archives/edgar/data/1982708/000121390025002551/ea0200357-11.htm>.

This presentation contains forward-looking statements, including statements about the Company's business outlook, strategy and market opportunities, and statements that may suggest trends for its business. All statements contained in this presentation other than statements of historical facts are individually and collectively forward-looking statements within the meaning of Section 27A of the Securities Act of 1933. The words "believe," "may," "should," "aim," "estimate," "continue," "anticipate," "intend," "will," "expect" and similar words are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions and expectations disclosed in these forward-looking statements. These forward-looking statements made in reliance on the safe harbor provisions of this presentation are based on estimates and information available to the Company at the time of this presentation. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict and beyond the Company's control. Therefore, prospective investors are cautioned that actual results may differ materially from those expressed or implied in the forward-looking statements herein. We urge you to review the risk factors discussed in the "Risk Factors" section of the Company's registration statement on Form F-1 for a discussion of the risks and uncertainties. There can be no assurance that the forward-looking statements made during this presentation will in fact be realized. Except as otherwise required by applicable securities law, the Company and its representatives undertake no duty to update or revise forward-looking statements, whether as a result of new information, future events or otherwise. Considering these limitations, you should not make any investment decision in reliance on forward-looking statements contained in this prospectus. This presentation and any oral statements made in connection with this presentation do not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The Company's securities may only be sold pursuant to an effective registration statement filed with the SEC. See offering documents for further risks and disclosures. There are no guarantees that any specific outcome will be achieved. Past performance is not indicative of future results. Investments may be speculative, illiquid and there is a risk of loss.

Anbio

Preliminary Offering Summary

Issuer	Anbio Biotechnology
Exchange/Proposed Ticker	Nasdaq Global Market: NNNN
Offering Type	Initial Public Offering
Proposed Shares Offered	1,600,000 Class A Ordinary Shares
Proposed Price Range	\$5 - \$6 /Share
Use of Proceeds	1) Approximately 35% for expansion of sales and distribution network in the strategically selected markets 2) Approximately 20% for research and development 3) Approximately 45% for working capital and general corporate matters
Lock-up	Directors, executive officers, and shareholder who own 5% or more of the outstanding Class A Ordinary Shares: 180 days
Underwriter	AC Sunshine Securities LLC.

*See offering documents for further risks and disclosures. There are no guarantees that any specific outcome will be achieved. Past performance is not indicative of future results. Investments may be speculative, illiquid and there is a risk of loss.

Anbio

Anbio Biotechnology's unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide.

*See offering documents for further risks and disclosures. There are no guarantees that any specific outcome will be achieved. Past performance is not indicative of future results. Investments may be speculative, illiquid and there is a risk of loss.

Anbio

Table of Contents


1. Company Overview
2. Our Products
3. Industry Overview
4. Growth Strategies
5. Financials



*See offering documents for further risks and disclosures. There are no guarantees that any specific outcome will be achieved. Past performance is not indicative of future results. Investments may be speculative, illiquid and there is a risk of loss.

Anbio

Key Facts



*See offering documents for further risks and disclosures. There are no guarantees that any specific outcome will be achieved. Past performance is not indicative of future results. Investments may be speculative, illiquid and there is a risk of loss.

Anbio

Company Overview

Our Products

Industry Overview

Growth Strategies

Financials

Leadership Team

Significant leadership experience in the diagnostic space for developing and commercializing IVD instruments and consumables globally

MICHAEL LAU, PhD, MBA - Chief Executive Officer

- Ph.D. from University of California, Riverside
- M.B.A. from University of Wisconsin
- More than 10 years of experience in the life sciences industry

SUKI SONG, CPA - Chief Financial Officer

- Extensive financial expertise with 20+ years of experience.
- Proven leadership in audits and financial management roles.
- Highly qualified with CPA and multiple professional certifications.

CHRIS TIAN - Chief Business Officer

- Expert in business strategies.
- Business Director at VIKBAY AB prior to joining Anbio.
- Researcher for Amway prior to joining Anbio.

*See offering documents for further risks and disclosures. There are no guarantees that any specific outcome will be achieved. Past performance is not indicative of future results. Investments may be speculative, illiquid and there is a risk of loss.

Anbio

Company Overview

Our Products

Industry Overview

Growth Strategies

Financials

Anbio is a Global Diagnostic Company

DIAGNOSTIC COMPANY	<ul style="list-style-type: none">▶ Innovation driven▶ Platform for assay development▶ 5 different diagnostic platforms for biomarker detection	<ul style="list-style-type: none">▶ Diverse portfolio of mature diagnostic assays
GLOBAL BUSINESS	<ul style="list-style-type: none">▶ Global sales, marketing, and presence in the EU, APAC, and the Americas▶ CE Marked diagnostic products	<ul style="list-style-type: none">▶ Rapidly growing customer base
GOOD IP POSITION	<ul style="list-style-type: none">▶ Developed know-hows for diagnostic analyzer and assay development	<ul style="list-style-type: none">▶ Proprietary technology across all 5 diagnostic solutions▶ 12 patent applications currently in review
HIGHLY SKILLED TEAM	<ul style="list-style-type: none">▶ Strong R&D foundation for diagnostic assay development▶ Dedicated and experienced management team	<ul style="list-style-type: none">▶ Strong manufacturing source

*See offering documents for further risks and disclosures. There are no guarantees that any specific outcome will be achieved. Past performance is not indicative of future results. Investments may be speculative, illiquid and there is a risk of loss.

Anbio

Company Overview

Our Products

Industry Overview

Growth Strategies

Financials

THE HEALTHCARE LANDSCAPE IS EVOLVING



Patient Healthcare



Increasing importance of Chronic Disease Management



Declining Population Health



More focus on Precision Medicine



High Demand for In-Vitro Diagnostics

*See offering documents for further risks and disclosures. There are no guarantees that any specific outcome will be achieved. Past performance is not indicative of future results. Investments may be speculative, illiquid and there is a risk of loss.

Anbio

Company Overview

Our Products

Industry Overview

Growth Strategies

Financials

Improve Healthcare by Decentralization

Our portfolio of instruments and R&D Platform is intended to better patient's quality of life by making diagnostics faster, more accessible, and more affordable globally



ANBIO'S DIAGNOSTIC SOLUTION:



*See offering documents for further risks and disclosures. There are no guarantees that any specific outcome will be achieved. Past performance is not indicative of future results. Investments may be speculative, illiquid and there is a risk of loss.

Anbio

Company Overview


Our Products

Industry Overview

Growth Strategies

Financials

ANBIO IS PAVING THE WAY OF THE FUTURE FOR DECENTRALIZED HEALTHCARE



TRADITIONAL CARE DIAGNOSTICS

- ▶ Long time for test results
- ▶ Samples are sent to central laboratories
- ▶ Doctors are limited to tests that can be reimbursed by insurance

OUR DIAGNOSTICS SOLUTION

- ▶ Rapid results within 20 minutes at the site of care
- ▶ Samples are processed at the site of care
- ▶ HCP can interpret test results and prescribe treatment to the patient in just one visit
- ▶ Tests can be conducted by HCP and interpreted together with the patient

*See offering documents for further risks and disclosures. There are no guarantees that any specific outcome will be achieved. Past performance is not indicative of future results. Investments may be speculative, illiquid and there is a risk of loss.

Anbio

Company Overview

Our Products

Industry Overview

Growth Strategies

Financials

Our Products

We are a Diagnostics Solutions Provider

Anbio's Fluorescent Immunochromatographic Solution (FIA)

Portable reader with available assays suitable for laboratory, wellness, and point-of-care applications.

Anbio's Chemiluminescent Immunoassay Solution (CLIA)

Automated and compact analyzer with available assays suitable for laboratory and wellness applications.

Anbio's RT-PCR Solution (MDx)

Assays suitable for laboratory application.

Anbio's Lateral Flow Assay (Colloidal Gold) Solution (LFIA)

Solution for visually detecting specific biomarker(s) in samples

Anbio's Loop-Mediated Isothermal Amplification Solution (LAMP)

Molecular diagnostic technique used to amplify and detect specific DNA or RNA sequences.

*See offering documents for further risks and disclosures. There are no guarantees that any specific outcome will be achieved. Past performance is not indicative of future results. Investments may be speculative, illiquid and there is a risk of loss.

Anbio

Company Overview

Our Products

Industry Overview

Growth Strategies

Financials

Anbio's Comprehensive Portfolio of Diagnostic Assays

Assays for Detection of Disease Biomarkers



INFECTIOUS DISEASES

- ▶ Infectious diseases assays available for FIA, CLIA, MDx, and LFIA platforms



CANCER

- ▶ Cancer assays available for FIA, CLIA, and LFIA platforms



Molecular Diagnostics

- ▶ Molecular diagnostic assays suitable for both pharmacogenetics and disease detection



CARDIOVASCULAR

- ▶ Cardiovascular assays available for FIA, LFIA, and CLIA platforms



HORMONES

- ▶ Hormone assays available for FIA, LFIA, and CLIA platforms



DRUG OF ABUSE

- ▶ Drug of abuse assays available for FIA and LFIA platforms

*See offering documents for further risks and disclosures. There are no guarantees that any specific outcome will be achieved. Past performance is not indicative of future results. Investments may be speculative, illiquid and there is a risk of loss.

Anbio

Company Overview

Our Products

Industry Overview

Growth Strategies

Financials

OUR PRODUCT DEVELOPMENT PHILOSOPHY

Anbio adheres to **three key principles** when developing our diagnostic products




INNOVATION

- ▶ We focus on diagnostic technology driven by mobility and ease of use.



AFFORDABLE

- ▶ We provide affordable diagnostic solutions and eliminate financial barriers often seen in our current system.



SPEED

- ▶ We focus on rapid test results for faster health solutions.

*See offering documents for further risks and disclosures. There are no guarantees that any specific outcome will be achieved. Past performance is not indicative of future results. Investments may be speculative, illiquid and there is a risk of loss.

Anbio

Company Overview

Our Products

Industry Overview

Growth Strategies

Financials

ANBIO'S FIA SOLUTION – ANALYZER

Easy to Use Portable Reader for Quantitative Biomarker Detection

ANBIO BIOTECHNOLOGY

AF-100S

Handheld Fluorescent Chromatographic
Immunoassay (FIA) Solution



Compatible with
many sample types



Mobile and High
Throughput

The Anbio AF-100S is a handheld, easy-to-use, affordable, and rapid point-of-care FIA that utilizes an LED light source from the reader for excitation of fluorescent dye for immunochromatographic qualitative or quantitative testing of analytes in whole blood and urine samples, including hormones detection, myocardial disease detection, infectious disease detection, and tumor-related antigens detection.

*See offering documents for further risks and disclosures. There are no guarantees that any specific outcome will be achieved. Past performance is not indicative of future results. Investments may be speculative, illiquid and there is a risk of loss.

Anbio

Company Overview

Our Products

Industry Overview

Growth Strategies

Financials

ANBIO'S ADL i1910 CLIA SOLUTION

Fully Automated Chemiluminescence Immunoassay Solution

ANBIO BIOTECHNOLOGY

ADL i1910



Compatible with many sample types



Mobile and High Throughput

The Anbio ADL i1910 is a fully automated, compact, and affordable CLIA analyzer that adopts direct chemiluminescence method based on acridinium ester and works clinically with supporting reagents for qualitative or quantitative testing of analytes in human serum, plasma, whole blood and urine samples, including hormones detection, myocardial disease detection, infectious disease detection, and tumor-related antigens detection.

Clinical immunodiagnostic solution with commercial-ready immunoassays for qualitative or quantitative testing of analytes

High throughput

Small footprint and won't take up too much lab space

Easy to use graphic user interface with large color touch screen

*See offering documents for further risks and disclosures. There are no guarantees that any specific outcome will be achieved. Past performance is not indicative of future results. Investments may be speculative, illiquid and there is a risk of loss.

Anbio

Company Overview

Our Products

Industry Overview

Growth Strategies

Financials

ANBIO'S LFIA SOLUTION



Compatible with
many sample types



Mobile and High
Throughput

Anbio's LFIA utilizes the immunochromatography principle for visual detection of a specific biomarker in a sample. With available high-quality assays to visually detect analytes for various abnormalities including cardiovascular, cancer, infectious diseases, drug abuse, and hormone, the Anbio LFIA (Colloidal Gold) is easy to use and can generate accurate test results within 20 minutes without the need of expensive instrumentation.

Anbio LFIA assays for the qualitative detection of cardiovascular, cancer, hormone, infectious disease, drug of abuse biomarkers within 15-20 minutes

Easy to use and affordable

*See offering documents for further risks and disclosures. There are no guarantees that any specific outcome will be achieved. Past performance is not indicative of future results. Investments may be speculative, illiquid and there is a risk of loss.

Anbio

Company Overview

Our Products

Industry Overview

Growth Strategies

Financials

ANBIO'S LAMP SOLUTION

Easy to Use, Portable MDx Testing



Compatible with
many sample types



Mobile and High
Throughput

Anbio's LAMP Solution, or Loop-Mediated Isothermal Amplification, is a diagnostic technique used to amplify and detect specific DNA or RNA sequences. The LAMP assay is used for various applications, including the detection of infectious diseases, genetic disorders, and foodborne pathogens. Anbio's LAMP solution is suitable for point-of-care diagnostics.

Anbio LAMP solution for the quantitative
detection molecular biomarkers within 20
minutes

For Point-of-Care Application

Ready to use, all in one LAMP kit

*See offering documents for further risks and disclosures. There are no guarantees that any specific outcome will be achieved. Past performance is not indicative of future results. Investments may be speculative, illiquid and there is a risk of loss.

Anbio

Company Overview

Our Products

Industry Overview

Growth Strategies

Financials

ANBIO'S PHARMACOGENOMICS SOLUTION

RT-PCR Assay to Enhance HCP Analysis



Compatible with most RT-PCR readers



Customizable

TARGET APPLICATIONS

Anbio simplifies the challenges faced in pharmacogenomics with our real-time PCR (RT-PCR) solutions approach that caters to the needs of both new and experienced users in quantitative reverse transcriptase PCR (qRT-PCR) and pharmacogenomics. Anbio's portfolio of pharmacogenomics assays supports HCP's analysis of genetic variations that affect drug metabolism, efficacy, and toxicity to determine personalized treatment options. Our reagent kits are compatible with most RT-PCR readers and can support user customization and optimization for even the most demanding assays.

Anbio RT-PCR has fast cycling protocols and throughput

Optimized and customizable for your sample type

*See offering documents for further risks and disclosures. There are no guarantees that any specific outcome will be achieved. Past performance is not indicative of future results. Investments may be speculative, illiquid and there is a risk of loss.

Anbio

Company Overview

Our Products

Industry Overview

Growth Strategies

Financials

WINNING THE GLOBAL DIAGNOSTIC MARKET

Anbio is **Well Positioned to Win** in a Growing Global Diagnostic Market

Immunoassays are emerging as a reliable field for aiding in the diagnosis and treatment guidance of cardiovascular diseases, infectious diseases, and cancer. The global immunoassay market exhibits a positive CAGR due to the increasing prevalence of chronic diseases.

*Source: BCC Research, LLC



Significant advancements in technology, such as ChLIA, which have evolved from measuring single analytes to utilizing multiplex bead-based technology for measuring autoantibodies is facilitating the diagnosis of complex diseases in the field of in-vitro diagnostics and point-of-care testing.

The size of the **global ChLIA market** in 2020 was \$7.2 billion and this segment is expected to grow at a CAGR of 6.5% to reach more than \$15.3 billion in 2032. The global ChLIA market is driven by several factors, such as the growing product innovations and development of ChLIA systems by market players, integration of technological advancements to address growing diagnostic needs of chronic diseases.

The size of the **global FIA market** in 2020 was \$4.2 billion and is expected to grow at a CAGR of 5.0% to reach \$6.9 billion in 2032. Increasing adoption of FIA applications in diagnosis of infectious and chronic diseases coupled with increasing investments to develop novel FIA technology products are the major factors driving the growth of this segment.

The size of the **global LFIA market** in 2020 was \$10.4 billion and is expected to reach nearly \$16.2 billion by 2032, with a CAGR of 6.9%. The demand for rapid diagnosis of COVID-19 has declined and anticipated this trend will continue as the pandemic is at endemic stage. In another scenario if disease hits globally, then this LFIA market will grow at double digits in order to meet another unprecedented testing demand. Otherwise, LIFA tests for infectious diseases and pregnancy are the major contributors of this market.

*Source: BCC Research, LLC

*See offering documents for further risks and disclosures. There are no guarantees that any specific outcome will be achieved. Past performance is not indicative of future results. Investments may be speculative, illiquid and there is a risk of loss.

Anbio

Company Overview

Our Products

Industry Overview

Growth Strategies

Financials

WINNING THE GLOBAL DIAGNOSTIC MARKET

Anbio is **Well Positioned to Win** in a Growing Global Diagnostic Market

Global RT-PCR Market

CAGR 6.8%

\$10.9B → **\$19.6B**
In 2023 In 2032

PCR testing is one of the most valuable techniques currently used in bioscience, diagnostics, and forensic science. In response to the pandemic, laboratories are equipped with high volume PCR testing for COVID-19 in order to increase the testing capacity and preferring RT-PCR as gold standard technique to diagnosis infections such as COVID-19, influenza, HIV are major reasons driving this market*.

*Source: BCCResearch

**Source: Isothermal Nucleic Acid Amplification Technology Market Size, Share & Trends Analysis Report By Product, By Technology (NASBA, HDA, LAMP, SDA, SPIA, NEAR), By Application, By End-use, By Region, And Segment Forecasts, 2023 – 2030.

*See offering documents for further risks and disclosures. There are no guarantees that any specific outcome will be achieved. Past performance is not indicative of future results. Investments may be speculative, illiquid and there is a risk of loss.

The global **Loop-Mediated Isothermal Amplification (LAMP)** market size was valued at USD 4235.34 million in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 12.3% from 2023 to 2030. The Loop-Mediated Isothermal Amplification (LAMP) technology is experiencing a notable surge in demand as a molecular testing technique, primarily attributed to the growing prevalence of infectious diseases. Tuberculosis, hepatitis, and influenza are among the leading causes of deaths caused by infectious diseases, especially in the developing countries. As a result, demand for rapid, user-friendly, and disease-specific testing options is expected to boost the adoption of LAMP offerings**.

Anbio

Company Overview

Our Products

Industry Overview

Growth Strategies

Financials

ANBIO'S GO-TO-MARKET STRATEGY

Strategic Approach to **Expand** Our IVD Market Share

Market Expansion and Regulatory Approval

- Focus on expanding global IVD market share through maturing and expanding sales, marketing, and distribution teams.
- Target key regions: EU, APAC, North America, South America, and Africa.
 - U.S. business model includes authorized regulatory diagnostics and lab-developed tests (LDT) channels.

Promote Diagnostic Products with Global and Regional Market Conditions in Mind

- Promote mature line of IVD products globally for continued growth.
- Diverse product portfolio including FIA, LFIA, PCR, LAMP, and ChLIA.
- Expanded customer portfolio to mitigate regional market recessions.

Provide Superior Quality Products and Customer Service

- Collaborate with third-party laboratories for IVD product development.
- Rigorous quality control testing for batch consistency.
- Experienced Field Application Scientists (FAS) and sales team for customer service.
- Fast product delivery through optimized logistics.

Establish a Global Customer Base


- Expansion across APAC, EU, Africa, and Americas.
- Diversified customer portfolio to mitigate economic cycling impact.

Diversify Portfolio of IVD Products via Sales and Marketing

- Concentric diversification approach in IVD sector.
 - Market research, product development, and cross-selling to existing clients.
- New product developments targeting niches within IVD field.

Focus on Efficient Manufacturing and Cost Management

- Strive for operational excellence to provide high-quality products at competitive prices.
- Suppliers' personnel examine costs and profitability by product, plant, and region.
 - Leverage skilled manufacturing and supply chain management processes.



*See offering documents for further risks and disclosures. There are no guarantees that any specific outcome will be achieved. Past performance is not indicative of future results. Investments may be speculative, illiquid and there is a risk of loss.

Anbio

Company Overview

Our Products

Industry Overview

Growth Strategies

Financials

Competitive Advantages

Our Advantages to Capture the Market Opportunities in the IVD Space



Speed, Innovation and Low-Cost

Given that global healthcare emphasis is shifting toward precision medicine, population health, and chronic disease management, Anbio develops and sell solutions to laboratory diagnostics and point-of-care technology in strategically selected markets. With a focus on low-cost, accessible IVD solutions, we offer a variety of mobile diagnostic instruments to detect diseases in patients who need treatment



Large Scale Manufacturing and Supply Capability

The supply chain we utilize to manufacturing our products may require a large amount of raw material consumption, allowing favorable financing terms, driving down the cost of goods, and exhibiting economies of scale. These factors promote maintain lean manufacturing processes, lowering the transfer price and maximizing our gross profit margin.



Experienced and Proven Management Team

Our management team has significant leadership experience in the diagnostic space for developing and commercializing IVD instruments and consumables globally.

*See offering documents for further risks and disclosures. There are no guarantees that any specific outcome will be achieved. Past performance is not indicative of future results. Investments may be speculative, illiquid and there is a risk of loss.

Anbio

Company Overview

Our Products


Industry Overview

Growth Strategies

Financials

Financial Highlights


Revenue FY2022 versus FY 2023




Revenue - 2023 versus 2024 (6 months)



FY2022 Revenue Breakdown by Region



FY2023 Revenue Breakdown by Region



*See offering documents for further risks and disclosures. There are no guarantees that any specific outcome will be achieved. Past performance is not indicative of future results. Investments may be speculative, illiquid and there is a risk of loss.

Anbio

Company Overview

Our Products


Industry Overview

Growth Strategies


Financials

Financial Highlights


Gross Profit - FY2022 versus 2023




Net Income - FY2022 versus FY2023



Gross Profit - 2023 versus 2024 (6 months)



Net Income - 2023 versus 2024 (6 months)



*See offering documents for further risks and disclosures. There are no guarantees that any specific outcome will be achieved. Past performance is not indicative of future results. Investments may be speculative, illiquid and there is a risk of loss.

Anbio

Company Overview

Our Products

Industry Overview

Growth Strategies

Financials

Anbio Biotechnology

Improving Prognosis by Decentralizing Diagnostics



info@acsunshine.com

+1 689-689-9686

www.acsunshine.com

*See offering documents for further risks and disclosures. There are no guarantees that any specific outcome will be achieved. Past performance is not indicative of future results. Investments may be speculative, illiquid and there is a risk of loss.